SCM
DNTH icon

SCS Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

SCS Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$914K Hold
9,375
– – 0.01% 302
2026
Q1 		$787K Hold
9,375
– – 0.01% 305
2025
Q4 		$386K Hold
9,375
– – ﹤0.01% 401
2025
Q3 		$369K Buy
+9,375
New +$240K ﹤0.01% 423

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

SCS Capital Management's DNTH Position: Q2 2026 in Review

SCS Capital Management held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 9,375 shares worth $914K. The position accounts for 0.01% of the portfolio, ranked #302.

SCS Capital Management first reported a position in DNTH in Q3 2025 and has held it in 4 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • SCS Capital Management held 9,375 shares of Dianthus Therapeutics worth $914K as of Q2 2026.
  • SCS Capital Management left its Dianthus Therapeutics share count unchanged in Q2 2026.
  • Dianthus Therapeutics made up 0.01% of SCS Capital Management's portfolio in Q2 2026, its #302 holding.
  • SCS Capital Management first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on SCS Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.